MGX — Metagenomi Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1785279 ·
Last close
$1.19
Market Cap
$44.80M
52W High
$1.45
52W Low
$1.13
ADV30
176,263
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,248,000 | — | -24,587,000 | -23,059,000 | 196,953,000 | 25,306,000 | 59,168,000 |
| Dec 2025 | 3,911,000 | — | -24,367,000 | -22,528,000 | 221,103,000 | 41,722,000 | 62,507,000 |
| Sep 2025 | 8,659,000 | — | -22,839,000 | -20,393,000 | 247,937,000 | 32,773,000 | 69,490,000 |
| Jun 2025 | 8,513,000 | — | -20,987,000 | -19,908,000 | 272,284,000 | 26,850,000 | 76,453,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-87,225,000
Investing CF
$82,787,000
Financing CF
$-306,000
CapEx
$-311,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.38
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-310,870,000
Inventory
—
Receivables
$305,000
ST Investments
$119,077,000
EBIT TTM
$-96,013,000
Pretax Income TTM
$-87,926,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$22,331,000
EBITDA
$-87,546,000
Free Cash Flow
$-56,654,500
Enterprise Value
$-56,176,240
Total Cash
$140,162,000
Total Debt
$39,186,000
Shares Out
37,646,858
Trailing EPS
$-2.29
Book Value
$3.66
ROE
-49.0%
ROA
-23.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 25,210,000 | -96,013,000 | -87,868,000 | 221,103,000 | 62,507,000 | — | -88,892,000 |
| Dec 2024 | 52,295,000 | -88,901,000 | -78,058,000 | 324,599,000 | 89,742,000 | — | -109,073,000 |
| Dec 2023 | 44,756,000 | -78,492,000 | -68,255,000 | 364,842,000 | 500,426,000 | — | -91,409,000 |
| Dec 2022 | 17,200,000 | -44,640,000 | -43,593,000 | 414,486,000 | 488,914,000 | — | 29,724,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.12
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TCRX | TScan Therapeutics, Inc. | $45.38M | $0.74 | — |
| EXOZ | EXOZYMES INC. | $43.16M | $4.65 | — |
| INMB | Inmune Bio, Inc. | $46.52M | $1.75 | — |
| SCLX | Scilex Holding Co | $46.87M | $6.66 | — |
| ATYR | aTYR PHARMA INC | $47.65M | $0.49 | — |
News headlines (Yahoo Finance, 1h cache)
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
2026-07-15 12:00 · Yahoo
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
2026-05-28 12:00 · Yahoo
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates
2026-05-14 13:42 · Yahoo
Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates
2026-05-12 00:05 · Yahoo
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
2026-05-11 20:05 · Yahoo
Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 21:15 · Yahoo
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
2026-04-16 11:00 · Yahoo
Spotlight On 3 ASX Penny Stocks With Market Caps Under A$2B
2026-04-02 20:02 · Yahoo
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates
2026-03-05 22:30 · Yahoo
Metagenomi Therapeutics: Q4 Earnings Snapshot
2026-03-05 21:28 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.